全文获取类型
收费全文 | 8960篇 |
免费 | 529篇 |
国内免费 | 43篇 |
专业分类
耳鼻咽喉 | 115篇 |
儿科学 | 237篇 |
妇产科学 | 167篇 |
基础医学 | 1471篇 |
口腔科学 | 275篇 |
临床医学 | 849篇 |
内科学 | 1290篇 |
皮肤病学 | 497篇 |
神经病学 | 1095篇 |
特种医学 | 399篇 |
外科学 | 1331篇 |
综合类 | 103篇 |
一般理论 | 6篇 |
预防医学 | 537篇 |
眼科学 | 200篇 |
药学 | 429篇 |
中国医学 | 1篇 |
肿瘤学 | 530篇 |
出版年
2023年 | 67篇 |
2022年 | 119篇 |
2021年 | 237篇 |
2020年 | 138篇 |
2019年 | 183篇 |
2018年 | 216篇 |
2017年 | 152篇 |
2016年 | 188篇 |
2015年 | 190篇 |
2014年 | 292篇 |
2013年 | 353篇 |
2012年 | 508篇 |
2011年 | 465篇 |
2010年 | 277篇 |
2009年 | 212篇 |
2008年 | 394篇 |
2007年 | 416篇 |
2006年 | 353篇 |
2005年 | 384篇 |
2004年 | 366篇 |
2003年 | 359篇 |
2002年 | 343篇 |
2001年 | 58篇 |
1999年 | 71篇 |
1998年 | 92篇 |
1997年 | 70篇 |
1996年 | 67篇 |
1995年 | 47篇 |
1994年 | 45篇 |
1993年 | 56篇 |
1992年 | 49篇 |
1988年 | 46篇 |
1985年 | 52篇 |
1982年 | 58篇 |
1980年 | 59篇 |
1979年 | 44篇 |
1933年 | 50篇 |
1932年 | 44篇 |
1931年 | 50篇 |
1930年 | 60篇 |
1928年 | 43篇 |
1927年 | 44篇 |
1926年 | 54篇 |
1923年 | 54篇 |
1922年 | 54篇 |
1921年 | 51篇 |
1914年 | 51篇 |
1913年 | 79篇 |
1912年 | 48篇 |
1911年 | 50篇 |
排序方式: 共有9532条查询结果,搜索用时 0 毫秒
101.
102.
103.
Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. 总被引:7,自引:0,他引:7
Freddie Bray Anja H Loos Peter McCarron Elizabete Weiderpass Mark Arbyn Henrik M?ller Matti Hakama D Max Parkin 《Cancer epidemiology, biomarkers & prevention》2005,14(3):677-686
Despite there being sufficient evidence for the effectiveness of screening by cytology in preventing cancer of the cervix uteri, screening policies vary widely among European countries, and incidence is increasing in younger women. This study analyzes trends in squamous cell carcinoma (SCC) of the cervix uteri in 13 European countries to evaluate effectiveness of screening against a background of changing risk. Age-period-cohort models were fitted and period and cohort effects were estimated; these were considered as primarily indicative of screening interventions and changing etiology, respectively. A unique set of estimates was derived by fixing age slopes to one of several plausible age curves under the assumption that the relation between age and cervical cancer incidence is biologically determined. There were period-specific declines in cervical SCC in several countries, with the largest decreases seen in northern Europe. A pattern emerged across Europe of escalating risk in successive generations born after 1930. In the western European countries, a decrease followed by a stabilization of risk by cohort was accompanied by period-specific declines. In southern Europe, stable period, but increasing cohort trends, were observed. Substantial changes have occurred in cervical SCC incidence in Europe and well-organized screening programs have been highly effective in reducing the incidence of cervical SCC. Screening and changing sexual mores largely explain the changing period- and cohort-specific patterns, respectively. The increasing risk in recent cohorts is of obvious concern particularly in countries where no screening programs are in place. Further investigation of the effectiveness of opportunistic screening is warranted as is the observation of differing risk patterns in young cohorts in countries with relatively similar societal structures. 相似文献
104.
105.
106.
107.
Sara Stoneham Matthew Murray Benjamin Thomas Max Williamson Christopher Sweeney Lindsay Frazier 《Pediatric blood & cancer》2019,66(8)
Testis cancer is considered a rare‐incidence cancer but comprises the third most common cancer diagnosed within the adolescent and young adult (AYA) years (15–39 years). Most testis cancer patients can anticipate a survival outcome in excess of 95%. However, there are subgroups of AYA patients where outcomes are considerably worse, including younger adolescents, patients with certain histological subtypes, or from certain ethnic backgrounds. For those cured with chemotherapy, the toxicity of treatment and burden of late effects is significant. Newer germ cell tumor–specific biomarkers may identify patients who do not require further treatment interventions or may detect early recurrence, potentially reducing the burden of treatment required for cure. An international collaboration for this rare tumor is creating the forum for trial design, where these biomarker research questions are embedded. Going forward, AYA testis cancer patients could benefit from having a more personalized treatment plan, tailored to risk, that minimizes the overall burden of late effects. 相似文献
108.
Renaud Sabatier Ccile Vicier Sverine Garnier Arnaud Guille Nadine Carbuccia Nicolas Isambert Florence Dalenc Marie Robert Christelle Levy Jihane Pakradouni Jos Adelaïde Max Chaffanet Patrick Sfumato Emilie Mamessier Franois Bertucci Anthony Goncalves 《Molecular oncology》2022,16(10):2057
The phosphatidylinositol‐3‐kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is frequently activated in HER2‐negative breast cancer and may play a role in taxane resistance. The phase IB/II TAKTIC trial () has shown that combining a dual AKT and p70 ribosomal protein S6 kinase (p70S6K) inhibitor (LY2780301) taken orally with weekly paclitaxel in HER2‐negative advanced breast cancer is feasible, with preliminary evidence of efficacy. We wanted to explore whether circulating tumor DNA (ctDNA) may be a surrogate marker of treatment efficacy in this setting. Serial plasma samples were collected and cell‐free DNA was sequenced using low‐coverage whole‐genome sequencing, and analysis was completed with droplet digital polymerase chain reaction (PCR) for some patients with driver mutations. Baseline tumor fraction (TF) and TF after 7 weeks on treatment were compared to progression‐free survival (PFS) and the overall response rate. We also explored circulating copy number alterations associated with treatment failure. Of the 51 patients enrolled in the TAKTIC trial, at least one plasma sample was available for 44 cases (96 timepoints). All patients with tumor TP53, PI3KCA, or AKT1 mutations harbored at least one of these alterations in plasma. TF at inclusion was correlated with PFS (6m‐PFS was 92% for ctDNAneg patients vs 68% for ctDNApos cases; hazard ratio [HR] = 3.45, 95% confidence interval [CI] [1.34–8.90], P = 0.007). ctDNA status at week 7 was not correlated with prognosis. Even though most circulating copy number alterations were conserved at disease progression, some genomic regions of interest were altered in post‐progression samples. In conclusion, ctDNA detection at baseline was associated with shorter PFS in patients included in the TAKTIC trial. Plasma‐based copy number analysis may help to identify alterations involved in resistance to treatment. NCT01980277相似文献
109.
110.
Bergman E Kieler H Petzold M Sonesson C Axelsson O 《Acta obstetricia et gynecologica Scandinavica》2007,86(6):671-677
BACKGROUND: Antenatal identification of infants small for gestational age (SGA) improves their perinatal outcome. Repeated measurement of symphysis-fundus (SF) heights performed by midwives is the most widespread screening method for detection of SGA. However, the inefficiency of this method necessitates improved practices. Earlier start and more frequent SF measurements, which could be accomplished by self-administered measurements, might improve the ability to detect deviant growth. The present study was set up to evaluate whether pregnant women can reliably perform SF measurements by themselves. METHOD: Forty healthy women with singleton and ultrasound-dated pregnancies from 2 antenatal clinics in Uppsala, Sweden, were asked to perform 4 consecutive SF measurements once every week, from 20 to 25 weeks of gestation until delivery. The self-administered SF measurements were recorded and systematically compared with midwives' SF measurements. RESULTS: Thirty-three pregnant women performed self-administered SF measurements over a 14-week period (range: 1-21). The SF curves constructed from self-administered SF measurements had the same shape as previously constructed population-based reference curves. The variance for self-administered SF measurements was higher than that of the midwives. CONCLUSIONS: Pregnant women are capable of measuring SF heights by themselves, but with higher individual variance than midwives. Repeated measurements at each occasion can compensate for the higher variance. The main advantage of self-administered SF measurements is the opportunity to follow fetal growth earlier and more frequently. 相似文献